European Journal of Haematology

Article	Citations
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect	133
	68
	64
Issue Information	63
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway	60
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy	45
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes	42
Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma	40
Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates	34
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia	33
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation	30
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg	29
Issue Information	27
Pubertal Assessment and Growth in Patients With Hemoglobinopathies: A Longitudinal Multicenter Study on the Association With Ferritin Levels	27
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial	26
Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States	25
Efficacy and Tolerance of Cladribine for Non‐Langerhans Cell Histiocytosis	25
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes	24
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review	23
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study	22
Beyond Frailty Scores: Unmet Needs and Tailored Treatment Strategies in Patients With Chronic Lymphocytic Leukemia Aged ≥ 80 Years	20
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea	20
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma	20
Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization	20
Long‐term effectiveness of eculizumab: Data from the International PNH Registry	20

Bridging Trials and Real Life in Fixed‐Duration BTKi –Venetoclax for CLL : A Delphi‐Enhanced Synth	20
Issue Information	20
Enhancing thalassemia gene carrier identification in non‐anemic populations using artificial intelligence erythrocyte morphology analysis and machine	19
Vaccination in Multiple Myeloma: Challenges and Strategies	18
Characteristics and Risk Factors of Thrombotic Complications in Patients With Iron Deficiency Anemia	18
Impact of Gut Microbiota and Inflammatory Cytokines on Immune Thrombocytopenia	18
Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia	17
Soluble MIC‐A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma	16
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France	16
From Rh Blood Group Antigen Antibody Testing to “Transfusionomics”	16
	16
BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study	15
Are we ready for personalizedCAR‐Ttherapy?	15
Isatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma	15
Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept	15
Construction of Lymphoma Organoids and Applications in Tumor Microenvironment Research	15
Issue Information	15
Transfusion requirements and complication rate in β‐thalassemia intermedia due to heterozygous β‐globin gene mutation and triplicated α‐globin genes	15
Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review	15
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study	14
HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B‐cell acute lymphoblastic leukemia	14
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies	14
The Amyloidosis Intersection: Dual Amyloid Types in a Single Host	14
Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry	14
Home‐Based Daratumumab in Patients With Multiple Myeloma	13
Issue Information	13
Efficacy, Safety, and Treatment‐Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials	13
Relationship between hemoglobin, hemolysis, and transcranial Doppler velocities in children with sickle cell disease: Results from a long‐term natural history study in Italy in the era of multimodal t	13
Genome‐Wide Meta‐Analysis of 1 896 991 Individuals Identifies 31 Novel Risk Loci for Iron Deficiency Anemia	13
Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia	13
Epigenetics and In Silico Transcriptome Analysis of Pediatric Acute Myeloid Leukemia	13
Comparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM	13
Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series	13
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine	13
	13
Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma	12
Issue Information	12
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based GVHD	12
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis	12
Issue Information	12
T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions	12
Persistent decreased bone marrow CD3+CD56+ T lymphocytes are inversely associated with mature granulocytes in myelodysplastic syndromes	12
Outcomes of COVID‐19 hospitalizations in patients with sickle cell disease: A nationwide analysis	12
Specialist Palliative Care and the Use of Healthcare Services Among Patients With Multiple Myeloma: A Nationwide Cohort Study	12
Estrogen‐based hormonal therapy and the risk of thrombosis in COVID‐19 patients	11
Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists	11
Clinical and Laboratory Indicators of Pediatric Leukemia and Neuroblastoma in Musculoskeletal Presentations: A Retrospective Study From a Resource‐Limited Setting	11
Precision Anticoagulation: The Imperative Usage of DOACs for Disease‐Specific Risk Stratification in MPNs	11
Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia	11
Sequencing and combination of currentsmall‐moleculeinhibitors for chronic lymphocytic leukemia: Where is the evidence?	11

Efficacy and Safety of the C5 Inhibitor Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta‐Analysis	11
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program	11
Updating Efficacy of First‐Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab	11
Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis	11
Adherence and Quality of Life in Adult Patients With Haemophilia A, Haemophilia B and Von Willebrand Disease: A National Cross‐Sectional Survey	11
Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation	11
Relationships between T‐lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study	11
A post hoc analysis of PROTECT VIII Kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	11
	10
Influenza as a Less Commonly Recognized Cause of Hemophagocytic Lymphohistiocytosis: A Systematic Review of Case Reports and Case Series	10
Three cases of late‐onset post CAR‐T therapy isolated CNS relapse in R/R large B‐cell lymphoma	10
Primary Cutaneous B‐Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management	10
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population	10
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial	10
The incidence, complications, and treatment of iron deficiency in pregnancy	10
Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma	10
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study	10
Real‐World Experience With a ZUMA ‐1 Cohort 4 Adopted Approach to CRS and	10
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition	10
Hematological and genetic profiles of persons with co‐inherited heterozygous β‐thalassemia and supernumerary α‐globin genes	10
Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis	10
Long‐term haematological response and maintained immunological function after laparoscopic subtotal splenectomy in patients with hereditary spherocytosis	9
Global prevalence of anemia among women of reproductive age, 2000–2019	9
	9
Salvage Therapy in Multiple Myeloma With Prior T‐Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide	9
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study	9
Clinical outcomes of patients referred for asymptomatic neutropenia: A focus on racial disparities in hematology	9
	9
STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma	9
Impact of Preanalytical Sample Preparation on the Recovery Rate of Cryopreserved Allogeneic Hematopoietic Stem Cells	9
	9
Central Venous Access Device Complications in Children With Leukemia: A Systematic Review and Meta‐Analysis	9
	9
Second Primary Malignancies in Patients With B‐Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta‐Analysis	9
	9
Impact of Modern Strategies for Graft‐Versus‐Host Disease Prophylaxis on Relapse Risk in Matched‐Sibling or Unrelated Donor Hematopoietic Cell Transplantation: A Systematic Review and Meta‐Analysis of	9
Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia	9
Phenotype of BTK‐lacking myeloid cells during prolonged COVID‐19 and upon convalescent plasma	9
ProGraME: A novel flow cytometry algorithm for the diagnosis of low‐risk myelodysplastic syndromes in patients with cytopenia	9
Interferon gamma regulates a complex pro‐survival signal network in chronic lymphocytic leukemia	9
CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T‐Cell Acute Lymphoblastic Leukemia	9
Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges	8
Hematopoietic cell transplantation for telomere biology diseases: A retrospective single‐center cohort study	8
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir‐exposed CMV‐free population receiving PTCy	8
Vitamin B12 Deficiency in Sickle Cell Disease: Method‐Driven Estimates and Systematic Diagnostic Misclassification	8
Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on theEORTC‐Dutchlate effects cohort‐linked data	8
Patient‐Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non‐Transfusion‐Dependent β‐Thalassemia Treated in the BEYOND	8
Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study	8
Outcomes in Kaposi's sarcoma‐associated herpesvirus ‐associated primary effusion lymphoma and multicentric Castleman's	8
The applicability of the central line‐associated bloodstream infection ( CLABSI ) criteria for the evaluation of bacteremia episodes in pediatric onc	8
Relevance, Risks, and Benefits of Early‐Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023	8
Screening for multidrug‐resistant organisms in high‐risk hospitalized patients with hematologic diseases	8
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study	8
A precision‐based exercise program for patients with multiple myeloma	8
Trends and in‐hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002–2019)	8
Νοvel Therapies in High‐Risk Myelodysplastic Syndromes	8
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction	8
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management	8
Relationship Between Daily Step Count, Biological Markers, and Clinical Outcomes in Patients With Sickle Cell Anemia: A Cross‐Sectional Study	8
Endothelial Cells in Lymphomas	8
Bone marrow expression of CD68/CD163 macrophages, IL‐17 and FOXP3 cells in aplastic anemia and their relation to prognosis	8
Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53	8
Optimizing Pediatric Tunneled Central Venous Catheter Placement: A Height‐Based Approach for Precise Length Determination	8
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic le	8
Chimeric antigen receptor T cells for acute myeloid leukemia	8
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning	8
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia	8
Fetal Hemoglobin Decrease During Voxelotor Treatment	8
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms	8
Correction to “Global and Regional Burden of Vaccine‐Induced Thrombotic Thrombocytopenia, 1969–2023: Comprehensive Findings With Critical Analysis of the International Pharmacovigilance Database”	8
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis	8
Whole Blood Transcriptomic Analysis of Sickle Cell Trait	8
Appropriateness of inpatient intravenous iron therapy in a Swiss tertiary care hospital	7
Issue Information	7
Risk‐based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP)	7
Exercise in newly diagnosed patients with multiple myeloma: A randomized controlled trial of effects on physical function, physical activity, lean body mass, bone mineral density, pain, and quality of	7
A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia	7
The current challenges faced by people with hemophilia B	7
Validation of the GATMO score in predicting non‐relapse mortality following hematopoietic cell transplant in multiple myeloma patients	7
Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia	7

Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemoth	7
Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies	7
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy	7
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study	7
	7
Issue Information	7
Clinical Management of Persistent Hypereosinophilia	7
Treatment of Refractory Monoclonal Immunoglobulin Deposition Disease With BCMA Bispecific Antibody	7
Evaluation of soluble P‐selectin as a predictive biomarker in acute symptomatic pulmonary embolism: Insights from a prospective observational study	7
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose	7
Core Needle Biopsies in Patients With Lymphoproliferative Malignancies: An Observational Single‐Center Cohort Study	7
Featured Cover	7
ABO Blood Type and Short‐Term Mortality in Patients With Infection‐Associated Disseminated Intravascular Coagulation	7
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care	7
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis	7
Effectiveness of progressive moderate‐vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with hemophilia: Secondary analysis of a randomized	7
Polypharmacy in Chronic Lymphocytic Leukemia in the Era of Targeted Agents: A Medication Stewardship Perspective	7
Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review	7
Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study	7
The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives	7
Recombinant factor IX Fc for the treatment of hemophilia B	7
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients	7
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents	7
Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry	7
Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients	7
Harnessing Polygenic Risk Scores to Refine Venous Thromboembolism Risk Stratification	7
Clonal Progression and Leukemic Transformation of a TP53 Mutated Post‐Polycythaemia Vera Myelofibrosis	7
Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults	6
Resveratrol and tetrahydroisoquinoline effects on neutrophil sensitivity to NETosis formation in low‐risk essential thrombocythemia patients	6
Hyper‐CVAD and Modified CALGB‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study	6
LP2, a stable lanthipeptide derived from cAng‐(1‐7), exerts myeloprotective action in mice	6
Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review	6
The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center	6
Distribution of ABO /Rh Blood Types Across Childhood Leukemia Subtypes: A Retrospective Cohort Study of 540 Pediatric Patients	6
Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen	6
Childhood autoimmune hemolytic anemia: A scoping review	6
Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti‐Myeloma Therapies	6
Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients	6
Risk Factors of Blood Culture Positivity and Mortality in Bloodstream Infections: A Population‐Based Study of Patients With B‐Cell Malignancies	6
First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens	6
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	6
CLLAF SCORE—A New Risk Score for Predicting Atrial Fibrillation in Treatment‐Naive CLL Patients Initiating First‐ and Second‐Generation BTK Inhibitor Therapy	6
Assessing the Burden of C5 Inhibitor Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria	6
Treatment horizon in multiple myeloma	6
The impact of hematology electronic consultations on the management of iron deficiency	6
Vaccination Uptake in Adults Post‐Haematopoietic Stem Cell Transplantation for B‐Cell Malignancies	6
Tandem bispecific CD123/CLL‐1 CAR‐T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia	6
Issue Information	6
	6
A Clinical Prediction Model for Inadequate Hemoglobin Response After Red Blood Cell Transfusion	6
Cytogenetic and molecular characteristics and outcomes of adult patients with early T‐cell precursor acute lymphoblastic leukemia	6
Immunophenotyping for the Assessment of Asymptomatic Lymphocytosis: A Retrospective Analysis and National Survey	6
The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review	6
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation	6
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients fr	6
Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens	6
Role of Nek2 and Hec1 in HTLV ‐1‐Infected T‐Cell Lines	6
Project Sickle Cure: A Prospective, International Observational Study of Hematopoietic Cell Transplantation for Sickle Cell Disease	6
Comparison of telomere length in patients with bone marrow failure syndromes and healthy controls	6
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups	6
The role of oral iron in the treatment of adults with iron deficiency	6
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia	5
Issue Information	5
Apheresis collection of mononuclear cells for chimeric‐antigen receptor therapies	5
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database	5
Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia	5
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies	5
Real‐World Evidence of Crizanlizumab Showing Reductions in Vaso‐Occlusive Crises and Opioid Usage in Sickle Cell Disease	5
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up	5
Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas	5
Correction to “Venetoclax‐Based Therapy for Relapsed or Refractory Acute Myeloid Leukaemia Following Intensive Induction Chemotherapy”	5
Thromboprophylaxis for inpatient with advanced cancer receiving palliative care: A retrospective study	5
A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies	5
Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma	5
Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010–2020: A retrospective analysis of electronic health records	5
Differences in patient‐reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis	5
Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings	5
Significance of Pre‐ and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core‐Binding Factor Acute Myeloid Leukemia	5
Effects of anti‐Xa activity monitoring on the outcome of high‐risk pregnancies treated with a prophylactic dose of low‐molecular‐weight heparin	5
Nivolumab Maintenance for Aggressive B‐Cell Lymphoma in Remission After First Line Therapy: A Phase 2 Clinical Trial	5
Issue Information	5
Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia	5
	5
Measurable Residual Disease in UBTF‐TD Adult Acute Myeloid Leukemia	5
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients	5
Iron Deficiency in the Presence of Anemia and Inflammation—A Sex‐Specific Cross‐Sectional Study	5
Development of Chimeric Antigen Receptor‐Modified NK  Cells for the Immunotherapy of Adult T‐Cell Leukemia/Lymphoma	5
Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic	5
Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia	5
ORPHEE: A Real‐World Study on rIX‐FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B	5
Imaging in Plasma‐Cell Neoplasms: Italian Experts’ Recommendations	5
Transition Into Clinical Routine and Survival Outcomes of BCL2 ‐ and BTK Inhibitors: An Analysis o	5
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation	5
Systematic review of hematopoietic stem cell gene therapy approach in thalassemia: Comparative analysis in animal models	5
Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics	5